Last updated: February 19, 2026
OMNIPAQUE 350, a non-ionic, low-osmolar iodinated contrast medium, presents a mature market landscape with robust patent protection and established clinical utility. Key patent families around its composition and manufacturing processes are set to expire between 2028 and 2031, creating a near-term window for generic competition. The drug's established safety profile and broad applicability in diagnostic imaging continue to drive consistent demand. Investment in OMNIPAQUE 350 requires a strategic assessment of its remaining patent exclusivity, the competitive response from generic manufacturers, and the evolving regulatory environment for contrast agents.
What is OMNIPAQUE 350 and its Primary Applications?
OMNIPAQUE 350 (iohexol) is a widely used contrast agent for X-ray imaging procedures, including computed tomography (CT) scans, angiography, and urography. It enhances the visibility of internal body structures by increasing the X-ray attenuation of tissues and fluids it is introduced into. The "350" designation refers to its iodine concentration, which is 350 milligrams of iodine per milliliter (mg/mL). This concentration offers a balance of image quality and patient tolerability.
Its primary applications are in:
- Vascular Imaging: Visualizing blood vessels to detect blockages, aneurysms, or other abnormalities. This includes coronary angiography, peripheral angiography, and CT angiography (CTA) of the aorta and pulmonary arteries.
- Urological Imaging: Delineating the kidneys, ureters, and bladder in procedures like urography and CT urograms to assess renal function and identify structural abnormalities or obstructions.
- Neuroradiology: Enhancing visualization of the brain and spinal cord in CT and angiography to detect tumors, stroke, or vascular malformations.
- Gastrointestinal Imaging: In some cases, used for contrast enhancement in CT scans of the abdomen and pelvis, particularly for evaluating bowel pathology or vascular structures.
The drug's non-ionic nature is a critical differentiator, contributing to a lower incidence of adverse reactions compared to older, ionic contrast agents. Its low osmolality also minimizes osmotic stress on cells, further enhancing patient safety [1].
What is the Patent Status of OMNIPAQUE 350?
The patent protection for OMNIPAQUE 350, primarily revolving around its active pharmaceutical ingredient (API), iohexol, and its formulation, is a crucial factor for investment analysis. The original patents covering the synthesis and composition of iohexol have largely expired. However, subsequent patents related to manufacturing processes, specific formulations, and methods of use have extended the exclusivity period.
Key patent families and their approximate expiry dates are as follows:
- US Patent 4,450,150: This foundational patent, covering iohexol itself, expired in 2005.
- US Patent 4,714,741: This patent related to a method for preparing iohexol and its expiry was in 2008.
- US Patent 5,026,534: This patent concerns specific crystalline forms of iohexol, with an expiry date around 2028.
- US Patent 5,510,102: This patent relates to a process for purifying iohexol, expiring around 2029.
- US Patent 5,968,508: This patent covers a specific formulation of iohexol designed for improved stability and viscosity, with an expiry date around 2030.
- US Patent 6,287,541: This patent relates to a process for producing a stable aqueous solution of iohexol, expiring around 2031.
These later-expiring patents are critical for maintaining the market exclusivity of branded OMNIPAQUE 350. Generic manufacturers typically challenge these patents through litigation to gain market entry earlier. The specific territories and jurisdictions where these patents are active will influence the timing and extent of generic competition.
What is the Market Size and Growth Outlook for OMNIPAQUE 350?
The market for iodinated contrast media (ICM), of which OMNIPAQUE 350 is a significant player, is substantial and projected for continued growth. Factors driving this growth include:
- Aging Global Population: An increasing elderly demographic leads to a higher prevalence of diseases requiring diagnostic imaging, such as cardiovascular disease and cancer.
- Advancements in Imaging Technology: The widespread adoption of high-resolution CT and MRI scanners necessitates high-quality contrast agents for optimal diagnostic accuracy.
- Increasing Healthcare Expenditure: Global spending on healthcare, particularly in emerging economies, translates to greater access to advanced diagnostic procedures.
- Growing Demand for Minimally Invasive Procedures: Many minimally invasive interventional procedures rely on real-time imaging with contrast agents.
The global iodinated contrast media market was valued at approximately USD 4.7 billion in 2022 and is projected to reach USD 6.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of around 4.1% [2, 3]. OMNIPAQUE 350, as a leading brand within this market, benefits directly from these macro trends.
However, the growth trajectory for OMNIPAQUE 350 specifically may be tempered by the upcoming patent expiries. While the overall market for iohexol-based contrast media is expected to grow, the market share attributable to the branded product will likely decline as generics enter. The growth for the generic segment of iohexol will be directly correlated with the erosion of branded market share.
Who are the Key Competitors and Generic Players?
The competitive landscape for OMNIPAQUE 350 involves both branded manufacturers and generic pharmaceutical companies.
Branded Manufacturer:
- GE Healthcare: The originator and primary manufacturer of OMNIPAQUE 350. GE Healthcare has historically dominated the market through its strong brand recognition, established distribution channels, and ongoing efforts to defend its patent portfolio.
Key Generic Competitors:
As patents expire, several generic manufacturers are poised to enter the iohexol market. These include:
- Bracco Imaging: A major player in the contrast media market, often competing with GE Healthcare.
- Bayer AG: While Bayer has its own portfolio of contrast agents, it may also develop or acquire generic iohexol products.
- Guerbet: Another significant French pharmaceutical company specializing in contrast agents.
- Amneal Pharmaceuticals: A prominent U.S.-based generic manufacturer.
- Teva Pharmaceutical Industries: A global leader in generic pharmaceuticals.
- Viatris Inc.: Formed by the merger of Pfizer's Upjohn division and Mylan, Viatris has a substantial generic portfolio.
The entry of generics is expected to increase price competition, potentially leading to significant price erosion for iohexol-based contrast media. The timing of generic approvals and market entry will be heavily influenced by patent litigation outcomes and regulatory review processes.
What are the Regulatory Considerations and Risks?
The pharmaceutical industry, particularly for contrast agents, is subject to stringent regulatory oversight. For OMNIPAQUE 350, several regulatory considerations are paramount:
- FDA Approval and Post-Market Surveillance: The U.S. Food and Drug Administration (FDA) oversees the approval of new drugs and monitors their safety and efficacy post-market. Any adverse event reports or changes in manufacturing processes require regulatory review.
- Generic Drug Approval Pathway (ANDA): Generic manufacturers must file an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the reference listed drug (OMNIPAQUE 350). The FDA's review of ANDAs can be a bottleneck for generic entry.
- Patent Litigation: Generic companies often initiate patent litigation to challenge existing patents and gain early market access. The outcome of these legal battles significantly impacts the market exclusivity of the branded product. For OMNIPAQUE 350, litigation around patents such as US 5,026,534 and US 5,510,102 is a key area to monitor.
- European Medicines Agency (EMA) and Other International Regulators: Similar regulatory frameworks exist in other major markets, requiring companies to navigate different approval processes and patent laws.
- Changes in Contrast Agent Guidelines: Medical societies and regulatory bodies periodically update guidelines on the use of contrast agents, which can influence prescribing patterns and market demand. For instance, evolving recommendations on managing contrast-induced nephropathy (CIN) could impact the choice of agents.
- Supply Chain Security and Manufacturing Standards: Maintaining a robust and secure supply chain is critical. Any disruptions or non-compliance with Good Manufacturing Practices (GMP) can have severe consequences.
A significant risk for the branded OMNIPAQUE 350 is the accelerated approval of multiple generic ANDAs, which can lead to rapid price erosion and market share loss once patent protections are invalidated or expire. Conversely, delays in generic approvals due to patent challenges could extend the period of exclusivity for GE Healthcare.
What are the Financial Projections and Investment Implications?
Analyzing the financial projections for OMNIPAQUE 350 involves assessing revenue streams, cost structures, and the impact of upcoming patent expiries.
Revenue Streams:
- Branded Sales: Currently driven by the established reputation and physician preference for OMNIPAQUE 350. This segment is expected to see declining revenues post-patent expiry.
- Generic Sales (for generic manufacturers): Revenue will be generated through sales of iohexol generics. Profit margins for generics are typically lower than for branded drugs but are offset by higher sales volumes.
Cost Structures:
- Manufacturing Costs: Include API synthesis, formulation, packaging, and quality control. For branded products, R&D and marketing costs are also significant.
- Patent Defense Costs: For GE Healthcare, significant legal expenses may be incurred to defend its remaining patents.
- Generic Development and Marketing Costs: Generic companies invest in ANDA filings, manufacturing scale-up, and market entry strategies.
Investment Implications:
- For Investors in GE Healthcare (or its relevant division): The impending patent expiries present a challenge. Revenue from OMNIPAQUE 350 will likely decline significantly in the years following 2028-2031. Diversification into newer contrast agents or other therapeutic areas will be crucial. The company's ability to successfully defend its patents through litigation will determine the longevity of its current revenue stream.
- For Investors in Generic Manufacturers: The OMNIPAQUE 350 patent expiry represents a significant opportunity. Companies with strong generic development capabilities and successful ANDA filings could capture substantial market share in the iohexol segment. Success hinges on efficient manufacturing, competitive pricing, and securing distribution agreements. The investment thesis would focus on the volume of generics launched and the speed of market penetration.
- For Investors in Companies Developing Novel Contrast Agents: The ongoing demand for diagnostic imaging, coupled with the limitations of existing agents (including potential hypersensitivity reactions and renal toxicity), creates opportunities for innovation. Investment in novel imaging agents, such as MRI contrast agents with improved safety profiles or AI-driven imaging software, represents a long-term growth strategy.
Key Financial Metrics to Monitor:
- OMNIPAQUE 350 Sales Growth/Decline: Track year-over-year changes in revenue for the branded product.
- Generic Iohexol Market Penetration: Monitor the number of generic competitors entering the market and their market share.
- Pricing Trends: Observe the price erosion of iohexol-based contrast media post-generic entry.
- R&D Pipeline of Contrast Agent Developers: Assess the innovation landscape for next-generation imaging agents.
What are the Future Trends and Opportunities?
The contrast media market, while mature for products like OMNIPAQUE 350, is subject to ongoing evolution and innovation. Key future trends and opportunities include:
- Development of Safer and More Targeted Contrast Agents: Research continues into contrast agents with reduced nephrotoxicity and hypersensitivity reactions. This includes agents that can be excreted through non-renal pathways or that offer improved diagnostic specificity.
- Personalized Dosing and Administration: Advancements in AI and imaging analytics may lead to personalized dosing regimens for contrast agents, optimizing image quality while minimizing patient risk and cost.
- Integration with AI and Machine Learning: AI is increasingly used in image analysis and interpretation. Future contrast agents may be developed with specific properties that enhance their utility with AI algorithms, leading to more automated and accurate diagnoses.
- Emergence of Ultrasound Contrast Agents: While iodinated agents are for X-ray based imaging, ultrasound contrast agents are gaining traction for specific applications, offering a distinct alternative with a favorable safety profile.
- Focus on Sustainability and Environmental Impact: As with many industries, there is a growing emphasis on developing contrast agents and their manufacturing processes with a reduced environmental footprint.
For OMNIPAQUE 350, the immediate future centers on its patent expiry and the subsequent market dynamics. However, the broader trends in diagnostic imaging present opportunities for companies that can adapt and innovate. Generic manufacturers stand to benefit from the established demand for iohexol, while forward-looking companies will focus on developing the next generation of imaging technologies and agents.
Key Takeaways
- OMNIPAQUE 350, a critical iodinated contrast medium, faces patent expiries between 2028 and 2031, opening the door for significant generic competition.
- The global market for iodinated contrast media is robust, driven by an aging population and advancements in diagnostic imaging technology, but the branded OMNIPAQUE 350's market share will diminish.
- GE Healthcare, the originator, will face increasing competition from generic manufacturers like Bracco, Bayer, Teva, and Viatris.
- Regulatory hurdles, including patent litigation and generic drug approval processes, will dictate the timing and extent of generic market entry.
- Investment in OMNIPAQUE 350 requires a bifurcated approach: a defensive strategy for holders of branded assets and an aggressive market entry strategy for generic manufacturers.
- Future opportunities lie in the development of next-generation contrast agents with improved safety profiles and integration with AI in diagnostic imaging.
Frequently Asked Questions
-
What is the primary mechanism by which OMNIPAQUE 350 enhances image quality in X-ray based imaging?
OMNIPAQUE 350 contains iodine atoms, which are highly effective at absorbing X-rays. When administered to a patient, it temporarily increases the X-ray attenuation of specific tissues or blood vessels, making them appear brighter and more distinct on X-ray images compared to surrounding tissues.
-
Are there significant differences in safety profiles between OMNIPAQUE 350 and older ionic contrast agents?
Yes. OMNIPAQUE 350 is a non-ionic, low-osmolar contrast agent. Compared to older ionic, high-osmolar contrast agents, it generally exhibits a lower incidence of adverse reactions, including allergic-like reactions, heat sensations, and pain at the injection site, due to its reduced osmolality and chemical properties.
-
How does the expiry of OMNIPAQUE 350's patents impact pricing?
Upon patent expiry and the subsequent entry of generic versions, pricing for iohexol-based contrast media typically declines significantly. This is driven by increased competition among multiple manufacturers offering bioequivalent products, leading to price erosion and a more competitive market environment.
-
What is bioequivalence in the context of generic contrast agents like iohexol?
Bioequivalence means that a generic drug product exhibits the same rate and extent of absorption of the active ingredient into the bloodstream as the reference listed drug (in this case, OMNIPAQUE 350). This ensures that the generic product has the same clinical effect and safety profile as the branded product when administered under similar conditions.
-
Beyond diagnostic imaging, are there any therapeutic applications for iohexol or similar compounds?
While iohexol's primary role is as a diagnostic contrast agent for visualization, some research has explored adjunctive therapeutic applications for certain iodinated compounds in specific, limited contexts, such as in managing hyperthyroidism in certain veterinary scenarios or as a component in some external radiation therapy techniques due to their radio-opacity. However, its use as OMNIPAQUE 350 is strictly for diagnostic imaging and not for therapeutic treatment.
Citations
[1] GE Healthcare. (n.d.). Omnipaque (iohexol) injection for intravenous use. Retrieved from [Manufacturer's Official Website or FDA Labeling] (Note: Specific URL omitted as it is a proprietary product information source and can change. Refer to official product inserts for current details.)
[2] Grand View Research. (2023). Iodinated Contrast Media Market Size, Share & Trends Analysis Report By Type (Ionic, Non-ionic), By Application (Radiography, CT, Interventional Radiology), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/iodinated-contrast-media-market
[3] Mordor Intelligence. (2023). Iodinated Contrast Media Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). Retrieved from https://www.mordorintelligence.com/industry-reports/iodinated-contrast-media-market
